Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.Antifungal Agents: Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.MycosesCandidiasis: Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)Aspergillosis: Infections with fungi of the genus ASPERGILLUS.Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.TriazolesCandida: A genus of yeast-like mitosporic Saccharomycetales fungi characterized by producing yeast cells, mycelia, pseudomycelia, and blastophores. It is commonly part of the normal flora of the skin, mouth, intestinal tract, and vagina, but can cause a variety of infections, including CANDIDIASIS; ONYCHOMYCOSIS; vulvovaginal candidiasis (CANDIDIASIS, VULVOVAGINAL), and thrush (see CANDIDIASIS, ORAL). (From Dorland, 28th ed)Echinocandins: Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.Mucormycosis: Infection in humans and animals caused by any fungus in the order Mucorales (e.g., Absidia, Mucor, Rhizopus etc.) There are many clinical types associated with infection of the central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an opportunistic infection in patients with a chronic debilitating disease, particularly uncontrolled diabetes, or who are receiving immunosuppressive agents. (From Dorland, 28th ed)Microbial Sensitivity Tests: Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).Antiprotozoal Agents: Substances that are destructive to protozoans.Candida albicans: A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis).Aspergillus fumigatus: A species of imperfect fungi from which the antibiotic fumigatin is obtained. Its spores may cause respiratory infection in birds and mammals.Aspergillus: A genus of mitosporic fungi containing about 100 species and eleven different teleomorphs in the family Trichocomaceae.Liposomes: Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins.Lung Diseases, Fungal: Pulmonary diseases caused by fungal infections, usually through hematogenous spread.Drug Combinations: Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.Drug Resistance, Fungal: The ability of fungi to resist or to become tolerant to chemotherapeutic agents, antifungal agents, or antibiotics. This resistance may be acquired through gene mutation.Meningitis, Cryptococcal: Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)Phosphatidylglycerols: A nitrogen-free class of lipids present in animal and particularly plant tissues and composed of one mole of glycerol and 1 or 2 moles of phosphatidic acid. Members of this group differ from one another in the nature of the fatty acids released on hydrolysis.Lipopeptides: Compounds consisting of a short peptide chain conjugated with an acyl chain.Peptides, Cyclic: Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.Ergosterol: A steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result in ERGOCALCIFEROL.Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.Cryptococcus neoformans: A species of the fungus CRYPTOCOCCUS. Its teleomorph is Filobasidiella neoformans.Drug Carriers: Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.Cryptococcosis: Infection with a fungus of the species CRYPTOCOCCUS NEOFORMANS.Zygomycosis: Infection in humans and animals caused by fungi in the class Zygomycetes. It includes MUCORMYCOSIS and entomophthoramycosis. The latter is a tropical infection of subcutaneous tissue or paranasal sinuses caused by fungi in the order Entomophthorales. Phycomycosis, closely related to zygomycosis, describes infection with members of Phycomycetes, an obsolete classification.Rhizopus: A genus of zygomycetous fungi of the family Mucoraceae, order MUCORALES, a common saprophyte and facultative parasite of mature fruits and vegetables. It may cause cerebral mycoses in diabetes and cutaneous infection in severely burned patients.Fungemia: The presence of fungi circulating in the blood. Opportunistic fungal sepsis is seen most often in immunosuppressed patients with severe neutropenia or in postoperative patients with intravenous catheters and usually follows prolonged antibiotic therapy.Fungi: A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies.Histoplasmosis: Infection resulting from inhalation or ingestion of spores of the fungus of the genus HISTOPLASMA, species H. capsulatum. It is worldwide in distribution and particularly common in the midwestern United States. (From Dorland, 27th ed)Mucorales: An order of zygomycetous fungi, usually saprophytic, causing damage to food in storage, but which may cause respiratory infection or MUCORMYCOSIS in persons suffering from other debilitating diseases.Polyenes: Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES.Natamycin: Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically.Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.Tuftsin: N(2)-((1-(N(2)-L-Threonyl)-L-lysyl)-L-prolyl)-L-arginine. A tetrapeptide produced in the spleen by enzymatic cleavage of a leukophilic gamma-globulin. It stimulates the phagocytic activity of blood polymorphonuclear leukocytes and neutrophils in particular. The peptide is located in the Fd fragment of the gamma-globulin molecule.Scedosporium: A mitosporic fungal genus previously called Monosporium. Teleomorphs include PSEUDALLESCHERIA.Ketoconazole: Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients.Pyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.Immunocompromised Host: A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.Trichosporon: A mitosporic fungal genus causing opportunistic infections, endocarditis, fungemia, a hypersensitivity pneumonitis (see TRICHOSPORONOSIS) and white PIEDRA.Central Nervous System Fungal Infections: MYCOSES of the brain, spinal cord, and meninges which may result in ENCEPHALITIS; MENINGITIS, FUNGAL; MYELITIS; BRAIN ABSCESS; and EPIDURAL ABSCESS. Certain types of fungi may produce disease in immunologically normal hosts, while others are classified as opportunistic pathogens, causing illness primarily in immunocompromised individuals (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME).Coccidioidomycosis: Infection with a fungus of the genus COCCIDIOIDES, endemic to the SOUTHWESTERN UNITED STATES. It is sometimes called valley fever but should not be confused with RIFT VALLEY FEVER. Infection is caused by inhalation of airborne, fungal particles known as arthroconidia, a form of FUNGAL SPORES. A primary form is an acute, benign, self-limited respiratory infection. A secondary form is a virulent, severe, chronic, progressive granulomatous disease with systemic involvement. It can be detected by use of COCCIDIOIDIN.Absidia: A genus of zygomycetous fungi, family Mucoraceae, order MUCORALES, which sometimes causes infection in humans.Azoles: Five membered rings containing a NITROGEN atom.Blastomycosis: A fungal infection that may appear in two forms: 1, a primary lesion characterized by the formation of a small cutaneous nodule and small nodules along the lymphatics that may heal within several months; and 2, chronic granulomatous lesions characterized by thick crusts, warty growths, and unusual vascularity and infection in the middle or upper lobes of the lung.Meningitis, Fungal: Meningitis caused by fungal agents which may occur as OPPORTUNISTIC INFECTIONS or arise in immunocompetent hosts.Colloids: Two-phase systems in which one is uniformly dispersed in another as particles small enough so they cannot be filtered or will not settle out. The dispersing or continuous phase or medium envelops the particles of the discontinuous phase. All three states of matter can form colloids among each other.Drug Resistance, Multiple, Fungal: The ability of fungi to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutations.Fat Emulsions, Intravenous: Emulsions of fats or lipids used primarily in parenteral feeding.Candida glabrata: A species of MITOSPORIC FUNGI commonly found on the body surface. It causes opportunistic infections especially in immunocompromised patients.Chemistry, Pharmaceutical: Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.Candida tropicalis: A species of MITOSPORIC FUNGI that is a major cause of SEPTICEMIA and disseminated CANDIDIASIS, especially in patients with LYMPHOMA; LEUKEMIA; and DIABETES MELLITUS. It is also found as part of the normal human mucocutaneous flora.Paecilomyces: A mitosporic fungal genus occasionally causing human diseases such as pulmonary infections, mycotic keratitis, endocarditis, and opportunistic infections. Its teleomorph is BYSSOCHLAMYS.Mycetoma: A chronic progressive subcutaneous infection caused by species of fungi (eumycetoma), or actinomycetes (actinomycetoma). It is characterized by tumefaction, abscesses, and tumor-like granules representing microcolonies of pathogens, such as MADURELLA fungi and bacteria ACTINOMYCETES, with different grain colors.Aspergillus flavus: A species of imperfect fungi which grows on peanuts and other plants and produces the carcinogenic substance aflatoxin. It is also used in the production of the antibiotic flavicin.Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.Dermatomycoses: Superficial infections of the skin or its appendages by any of various fungi.Colony Count, Microbial: Enumeration by direct count of viable, isolated bacterial, archaeal, or fungal CELLS or SPORES capable of growth on solid CULTURE MEDIA. The method is used routinely by environmental microbiologists for quantifying organisms in AIR; FOOD; and WATER; by clinicians for measuring patients' microbial load; and in antimicrobial drug testing.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Cryptococcus: A mitosporic Tremellales fungal genus whose species usually have a capsule and do not form pseudomycellium. Teleomorphs include Filobasidiella and Fidobasidium.Leishmania donovani: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes visceral leishmaniasis (LEISHMANIASIS, VISCERAL). The sandfly genera Phlebotomus and Lutzomyia are the vectors.Fusarium: A mitosporic Hypocreales fungal genus, various species of which are important parasitic pathogens of plants and a variety of vertebrates. Teleomorphs include GIBBERELLA.Histoplasma: A mitosporic Onygenales fungal genus causing HISTOPLASMOSIS in humans and animals. Its single species is Histoplasma capsulatum which has two varieties: H. capsulatum var. capsulatum and H. capsulatum var. duboisii. Its teleomorph is AJELLOMYCES capsulatus.Eye Infections, Fungal: Infection by a variety of fungi, usually through four possible mechanisms: superficial infection producing conjunctivitis, keratitis, or lacrimal obstruction; extension of infection from neighboring structures - skin, paranasal sinuses, nasopharynx; direct introduction during surgery or accidental penetrating trauma; or via the blood or lymphatic routes in patients with underlying mycoses.Invasive Pulmonary Aspergillosis: Lung infections with the invasive forms of ASPERGILLUS, usually after surgery, transplantation, prolonged NEUTROPENIA or treatment with high-doses of CORTICOSTEROIDS. Invasive pulmonary aspergillosis can progress to CHRONIC NECROTIZING PULMONARY ASPERGILLOSIS or hematogenous spread to other organs.Coccidioides: A mitosporic fungal genus which causes COCCIDIOIDOMYCOSIS.Pseudallescheria: Ascomycetous fungi, family Microascaceae, order Microascales, commonly found in the soil. They are causative agents of mycetoma, maduromycosis, and other infections in humans.Mitosporic Fungi: A large and heterogenous group of fungi whose common characteristic is the absence of a sexual state. Many of the pathogenic fungi in humans belong to this group.Phosphatidylcholines: Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a choline moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and choline and 2 moles of fatty acids.Culture Media: Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN.Cryptococcus gattii: A species of the fungus CRYPTOCOCCUS. Its teleomorph is Filobasidiella bacillispora.Chills: The sudden sensation of being cold. It may be accompanied by SHIVERING.Central Nervous System Protozoal Infections: Infections of the brain, spinal cord, or meninges by single celled organisms of the former subkingdom known as protozoa. The central nervous system may be the primary or secondary site of protozoal infection. These diseases may occur as OPPORTUNISTIC INFECTIONS or arise in immunocompetent hosts.Drug Resistance, Microbial: The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).Pulmonary Aspergillosis: Infections of the respiratory tract with fungi of the genus ASPERGILLUS. Infections may result in allergic reaction (ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS), colonization in pulmonary cavities as fungus balls (MYCETOMA), or lead to invasion of the lung parenchyma (INVASIVE PULMONARY ASPERGILLOSIS).Antimony Sodium Gluconate: Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.Sterols: Steroids with a hydroxyl group at C-3 and most of the skeleton of cholestane. Additional carbon atoms may be present in the side chain. (IUPAC Steroid Nomenclature, 1987)Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Endocarditis: Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.Aspergillosis, Allergic Bronchopulmonary: Hypersensitivity reaction (ALLERGIC REACTION) to fungus ASPERGILLUS in an individual with long-standing BRONCHIAL ASTHMA. It is characterized by pulmonary infiltrates, EOSINOPHILIA, elevated serum IMMUNOGLOBULIN E, and skin reactivity to Aspergillus antigen.Filipin: A complex of polyene antibiotics obtained from Streptomyces filipinensis. Filipin III alters membrane function by interfering with membrane sterols, inhibits mitochondrial respiration, and is proposed as an antifungal agent. Filipins I, II, and IV are less important.Kidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).Naegleria fowleri: A species of parasitic protozoa having both an ameboid and flagellate stage in its life cycle. Infection with this pathogen produces PRIMARY AMEBIC MENINGOENCEPHALITIS.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Drug Antagonism: Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy.Injections, Intravenous: Injections made into a vein for therapeutic or experimental purposes.Suspensions: Colloids with liquid continuous phase and solid dispersed phase; the term is used loosely also for solid-in-gas (AEROSOLS) and other colloidal systems; water-insoluble drugs may be given as suspensions.Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.Meningoencephalitis: An inflammatory process involving the brain (ENCEPHALITIS) and meninges (MENINGITIS), most often produced by pathogenic organisms which invade the central nervous system, and occasionally by toxins, autoimmune disorders, and other conditions.Prototheca: A genus of achlorophyllic algae in the family Chlorellaceae, and closely related to CHLORELLA. It is found in decayed matter; WATER; SEWAGE; and SOIL; and produces cutaneous and disseminated infections in various VERTEBRATES including humans.Lethal Dose 50: The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.Colorimetry: Any technique by which an unknown color is evaluated in terms of standard colors. The technique may be visual, photoelectric, or indirect by means of spectrophotometry. It is used in chemistry and physics. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Mycology: The study of the structure, growth, function, genetics, and reproduction of fungi, and MYCOSES.Meningitis: Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)

Lung weight parallels disease severity in experimental coccidioidomycosis. (1/2502)

Evidence provided by histopathological study of lesions is a valuable adjunct for evaluating chemotherapeutic efficacy in experimental animal models, In addition, this should be correlated with a measure of disease severity in the same animal. The latter could be obtained by homogenization of infected organs and quantitative enumeration of viable cells of the etiological agent, but this would preclude histopathological studies in the same animal. Progression of disease in pulmonary infection is associated with replacement of air space by fluid, cells, and cellular debris. Therefore, an increase in lung weight should reflect severity of disease. Results with the murine model of coccidioidomycosis demonstrate that increasing lung weight parallels the increasing census of fungus cells in the lungs of both treated and nontreated infected mice. This was supported with evidence obtained from microscopic studies of lesions indicating that specific chemotherapy limited spread of the infection and inhibited multiplication of the fungus in the lung. Therefore, lung weight can be used as a measure of disease severity in the murine model of coccidioidomycosis.  (+info)

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. (2/2502)

In August 1997, AmBisome (liposomal amphotericin B, Nexstar, San Dimas, CA) was the first drug approved for the treatment of visceral leishmaniasis by the U.S. Food and Drug Administration. The growing recognition of emerging and reemerging infections warrants that safe and effective agents to treat such infections be readily available in the United States. The following discussion of the data submitted in support of the New Drug Application for AmBisome for the treatment of visceral leishmaniasis shows the breadth of data from clinical trials that can be appropriate to support approval for drugs to treat tropical diseases.  (+info)

Early mycological treatment failure in AIDS-associated cryptococcal meningitis. (3/2502)

Cryptococcal meningitis causes significant morbidity and mortality in persons with AIDS. Of 236 AIDS patients treated with amphotericin B plus flucytosine, 29 (12%) died within 2 weeks and 62 (26%) died before 10 weeks. Just 129 (55%) of 236 patients were alive with negative cerebrospinal fluid (CSF) cultures at 10 weeks. Multivariate analyses identified that titer of cryptococcal antigen in CSF, serum albumin level, and CD4 cell count, together with dose of amphotericin B, had the strongest joint association with failure to achieve negative CSF cultures by day 14. Among patients with similar CSF cryptococcal antigen titers, CD4 cell counts, and serum albumin levels, the odds of failure at week 10 for those without negative CSF cultures by day 14 was five times that for those with negative CSF cultures by day 14 (odds ratio, 5.0; 95% confidence interval, 2.2-10.9). Prognosis is dismal for patients with AIDS-related cryptococcal meningitis. Multivariate analyses identified three components that, along with initial treatment, have the strongest joint association with early outcome. Clearly, more effective initial therapy and patient management strategies that address immune function and nutritional status are needed to improve outcomes of this disease.  (+info)

Systemic candidiasis with candida vasculitis due to Candida kruzei in a patient with acute myeloid leukaemia. (4/2502)

Candida kruzei-related systemic infections are increasing in frequency, particularly in patients receiving prophylaxis with antifungal triazoles. A Caucasian male with newly diagnosed acute myeloid leukaemia (AML M1) developed severe and persistent fever associated with a micropustular eruption scattered over the trunk and limbs during induction chemotherapy. Blood cultures grew Candida kruzei, and biopsies of the skin lesions revealed a candida vasculitis. He responded to high doses of liposomal amphotericin B and was discharged well from hospital.  (+info)

In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. (5/2502)

We evaluated the in vitro and in vivo potencies of a new lipid nanosphere that incorporates amphotericin B (AmB), NS-718, against Aspergillus fumigatus. The in vitro activity of NS-718 (the MIC at which 90% of strains are inhibited [MIC90], 0.25 microgram/ml) against 18 isolates of A. fumigatus was similar to that of deoxycholate AmB (D-AmB; Fungizone; MIC90, 0.25 microgram/ml), but NS-718 was more potent than liposomal AmB (L-AmB; AmBi-some; MIC90, 1.0 microgram/ml). The in vivo efficacy of NS-718 in a rat model of invasive pulmonary aspergillosis was compared with those of D-AmB and L-AmB. A low dose (1 mg/kg of body weight) of L-AmB was ineffective (survival rate, 0%), although equivalent doses of D-AmB and NS-718 were more effective (survival rate, 17%). However, a higher dose of NS-718 (3 mg/kg) was more effective (survival rate, 100%) than equivalent doses of D-AmB and L-AmB (survival rate, 0%). To explain these differences, pharmacokinetic studies showed higher concentrations of AmB in the plasma of rats treated with NS-718 than in the plasma of those treated with D-AmB. Our results suggest that NS-718, a new preparation of AmB, is a promising antifungal agent with activity against pulmonary aspergillosis.  (+info)

Effect of fasting on temporal variation in the nephrotoxicity of amphotericin B in rats. (6/2502)

Evidence for temporal variation in the nephrotoxicity of amphotericin B was recently reported in experimental animals. The role of food in these variations was determined by studying the effect of a short fasting period on the temporal variation in the renal toxicity of amphotericin B. Twenty-eight normally fed and 28 fasted female Sprague-Dawley rats were used. Food was available ad libitum to the fed rats, while the fasted animals were fasted 12 h before and 24 h after amphotericin B injection to minimize stress for the animals. Water was available ad libitum to both groups of rats, which were maintained on a 14-h light, 10-h dark regimen (light on at 0600 h). Renal toxicity was determined by comparing the levels of excretion of renal enzyme and the serum creatinine and blood urea nitrogen (BUN) levels at the time of the maximal (0700 h) or the minimal (1900 h) nephrotoxicity after the intraperitoneal administration of a single dose of dextrose (5%; control group) or amphotericin B (50 mg/kg of body weight; treated group) to the rats. The nephrotoxicities obtained after amphotericin B administration at both times of day were compared to the nephrotoxicities observed for time-matched controls. In fed animals, the 24-h urinary excretion of N-acetyl-beta-D-glucosaminidase and beta-galactosidase was significantly higher when amphotericin B was injected at 0700 and 1900 h. The excretion of these two enzymes was reduced significantly (P < 0.05) in fasting rats, and this effect was larger at 0700 h (P < 0.05) than at 1900 h. The serum creatinine level was also significantly higher (P < 0.05) in fed animals treated at 0700 h than in fed animals treated at 1900 h. Fasting reduced significantly (P < 0.05) the increase in the serum creatinine level, and this effect was larger in the animals treated at 0700 h. Similar data were obtained for BUN levels. Amphotericin B accumulation was significantly higher (P < 0.05) in the renal cortexes of fed rats than in those of fasted animals, but there was no difference according to the time of injection. These results demonstrated that fasting reduces the nephrotoxicity of amphotericin B and that food availability is of crucial importance in the temporal variation in the renal toxicity of amphotericin B in rats.  (+info)

Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. (7/2502)

The present study shows that a number of basic antifungal peptides, including human salivary histatin 5, a designed histatin analog designated dhvar4, and a peptide from frog skin, PGLa, are active against amphotericin B-resistant Candida albicans, Candida krusei, and Aspergillus fumigatus strains and against a fluconazole-resistant Candida glabrata isolate.  (+info)

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. (8/2502)

The in-vitro fungistatic and fungicidal activities of voriconazole were compared with those of itraconazole and amphotericin B. MICs for 110 isolates belonging to 11 species of filamentous fungi were determined by a broth microdilution adaptation of the method recommended by the National Committee for Clinical Laboratory Standards. Minimum lethal concentrations (MLCs) of the three antifungal agents were also determined. The MIC ranges of the three compounds were comparable for Aspergillus flavus, Aspergillus fumigatus, Cladophialophora bantiana and Exophiala dermatitidis. Voriconazole and itraconazole were more active than amphotericin B against Fonsecaea pedrosoi, but the two azole agents were less active against Sporothrix schenckii. Voriconazole was more active than itraconazole or amphotericin B against Scedosporium apiospermum, but less active than the other two agents against two mucoraceous moulds, Absidia corymbifera and Rhizopus arrhizus. Voriconazole and amphotericin B were more active than itraconazole against Fusarium solani. With the exception of S. apiospermum, all the moulds tested had MLC50 values of < or =2 mg/L and MLC90 values of < or =4 mg/L against amphotericin B. Voriconazole and itraconazole showed fungicidal effects against five of the 1 1 moulds tested (A. flavus, A. fumigatus, C. bantiana, E. dermatitidis and F. pedrosoi) with MLC90 values of < or =2 mg/L. In addition, voriconazole was fungicidal for Phialophora parasitica. Our results suggest that voriconazole could be effective against a wide range of mould infections in humans.  (+info)

C. lusitaniae is considered an opportunistic organism whose association with invasive infection has increased in recent years (1, 2, 3, 5, 16). Unlike Candida albicans, which is rarely resistant to amphotericin B, C. lusitaniae has consistently been associated with the failure of amphotericin B treatment in patients with invasive disease (3, 10, 14, 15). Resistance may be innate or may develop during treatment.. Here we report the first clinical case of C. lusitaniae developing amphotericin B resistance during amphotericin B treatment and exhibiting an accompanying difference in colony color on CAC between susceptible and resistant strains. The antifungal susceptibility tests performed according to the NCCLS M-27A macrobroth method by a reference laboratory showed a fourfold increase of the amphotericin B MIC for the isolate recovered after 7 weeks of amphotericin B treatment compared to that for an isolate recovered prior to amphotericin B treatment. The MIC of 1.0 μg/ml reported for the ...
Liposomal Amphotericin B Injection 50 mg, Liposomal Amphotericin B Injection IP 50 mg by UNITED BIOTECH (P) LTD. a manufacturer, supplier, exporter of Liposomal Amphotericin B Injection, Amphotericin B Injection. Call Now.
To assess the mortality and resource utilization that results from acute renal failure associated with amphotericin B therapy, 707 adult admissions in which parenteral amphotericin B therapy was given were studied at a tertiary-care hospital. Main outcome measures were mortality, length of stay, and costs; we controlled for potential confounders, including age, sex, insurance status, baseline creatinine level, length of stay before beginning amphotericin B therapy, and severity of illness. Among 707 admissions, there were 212 episodes (30%) of acute renal failure. When renal failure developed, the mortality rate was much higher: 54% versus 16% (adjusted odds of death, 6.6). When acute renal failure occurred, the mean adjusted increase in length of stay was 8.2 days, and the adjusted total cost was $29,823. Although residual confounding exists despite adjustment, the increases in resource utilization that we found are large and the associated mortality is high when acute renal failure occurs ...
Both intrinsic and acquired resistance to amphotericin B have been documented for Candida lusitaniae. Amphotericin B remains the drug of choice for many critical fungal infections, and the detection of resistance is essential to monitor treatment effectively. The limitations of the National Committee for Clinical Laboratory Standards (NCCLS) reference methodology for detection of amphotericin B resistance are well documented, and several alternative methods have been proposed. Etest assays with RPMI and antibiotic medium 3 (AM3) agar were compared to the NCCLS M27-A broth macrodilution method using AM3 for amphotericin B resistance testing with 49 clinical isolates of C. lusitaniae. The panel included nine isolates with known or presumed resistance to amphotericin B on the basis of in vivo and/or in vitro data. The distribution of amphotericin B MICs by Etest with RPMI ranged from 0.032 to 16 μg/ml and was bimodal. All of the putatively resistant isolates were inhibited by amphotericin B at ...
0196] Throughout this application, various publications are referenced, specifically including those listed below. All such references are incorporated herein by reference. [0197] Brajtburg, J., W. G. Powderly, G. S. Kobayashi and G. Medoff. 1990. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 34:183-188. [0198] Cagnoni, P. J., T. J. Walsh, M. M. Prendergast, D. Bodensteiner, S. Hiemenz, R. N. Greenberg, C. A. Arndt, M. Schuster, N. Seibel, V. Yeldandi, and K. B. Tong. 2000. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18(12):2476-83. [0199] Chavanet, P., V. Joly, D. Rigaud, J. Bolard, C. Carbon, P. Yeni. Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother. 1994;38(5):963-8. [0200] Cleary, J. D., R. L. Nolan, and S. W. Chapman. 1992 Inhibition of interleukin 1 release ...
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
Cryptococcal meningitis is a life-threatening infectious complication of AIDS. Because relapse after treatment occurs in over 50 percent of cases, chronic maintenance therapy with intravenous (IV) amphotericin B is usually given. However, amphotericin B is not always effective, has toxic effects, and must be given by the intravenous route. Fluconazole is an antifungal agent that can be given orally and has been shown to be effective against cryptococcal infections in animals and against acute CM in a few AIDS patients. Also, the side effects experienced by over 2000 patients or volunteers given fluconazole have seldom been severe enough to require withdrawal of the drug.. Patients accepted in the trial are randomly assigned to fluconazole or amphotericin B. Fluconazole is given orally once a day and amphotericin B is given intravenously once a week. Dosages depend on body weight. Medications may be given with amphotericin B to prevent or reduce discomfort from associated side effects. Patients ...
Efficacies of High-Dose Fluconazole plus Amphotericin B and High-Dose Fluconazole plus 5-Fluorocytosine versus Amphotericin B, Fluconazole, and 5-Fluorocytosine
Objective: Amphotericin B failure is frequently seen in patients with candidaemia caused by Candida rugosa. We evaluated amphotericin 13, fluconazole, posaconazole and voriconazole as alternative treatments against infection in mice with two isolates of C. rugosa.Methods: Neutropenic mice were inoculated intravenously with C. rugosa. Amphotericin 13, fluconazole, posaconazole and voriconazole were administered for 7 days after infection. Efficacy of the antifungal treatment was assessed by survival and tissue burden of C. rugosa.Results: All of the four drugs significantly prolonged survival over controls. With both isolates, kidney counts were reduced significantly below controls for amphotericin B, fluconazole and posaconazole. However, voriconazole was less effective than the other antifungals.Conclusion: Despite poor clinical response to amphotericin B, in vivo data indicate that amphotericin B increases organ clearance and survival over untreated controls. However, although voriconazole ...
Background. For patients with Indian visceral leishmaniasis, amphotericin B deoxycholate is usually given as 15 alternate-day infusions of 1 mg/kg over 30 days (total dose, 15 mg/kg); daily treatment with 1 mg/kg for 20 days (total dose, 20 mg/kg) is also used. This study was done to address the unsettled therapeutic questions of administration schedule (alternate-day vs. daily administration) and dose (1 vs. 0.75 mg/kg) and to determine whether the duration of amphotericin B treatment in Bihar, India, can be shortened to 15 days.. Methods. To compare alternate-day versus daily administration and 1-mg/kg versus 0.75-mg/kg doses and to determine whether the duration of treatment could be abbreviated, Indian subjects randomly received 15 infusions of 1 mg/kg (group A; 245 patients) or 0.75 mg/kg (group B; 244 patients) on alternate days or 1 mg/kg (group C; 500 patients) or 0.75 mg/kg (group D; 496 patients) daily. Noninferiority testing compared 6-month cure rates using a 5% margin.. Results. ...
Studies on Amphotericin B. Current Formulations and problems and where we fit in!. Scott C. Hartsel Chemistry Department University of Wisconsin-Eau Claire. Overview. An ominous threat What is Amphotericin B? The problem with Amphotericin B What are liposomes and what good are they?...
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia Stable (no update expected for reasons given in Whats new) answers are found in the Cochrane Abstracts powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
Sprawdź ile zapłacisz za lek amphotericin b lipid complex Intravenous, Injection w aptece, znajdź tańsze zamienniki leku. Określ swoje uprawnienia i sprawdź jakie zniżki Ci przysługują.
Amphotericin B is an antifungal medication that fights infections caused by fungus. Amphotericin B is used to treat serious, life-threatening fungal infections. It is not for use in treating a minor fungal infection such as a yeast infection of the mouth, esophagus, or vagina. Amphotericin B may also be used for...
The increased use of liposomal amphotericin B (L-AMB) in neonates has occurred without evidence of increased efficacy or safety, results of a retrospective analysis presented at IDWeek 2013.
Visceral Leishmaniasis, which is progressive and fatal if not treated, is an insidious, chronic disease that is characterized by irregular fever, anorexia, weight loss, cough, gross enlargement of the spleen and liver, mild anemia and emaciation. This may be preceded by rigors and vomiting. If untreated, Kala-azar, which is the most severe form of Leishmaniasis, has a mortality rate of nearly 100%.. The goal of the project is to establish that a single dose of AMPHOMUL® can be used to achieve a Definitive cure for Visceral Leishmaniasis leading to a short course therapy. The project will also seek to establish that AMPHOMUL ® is safe, at least as effective and more affordable than current treatment, and is without the risk of drug resistance.. The trial is a Prospective, Multicentric, Randomized, Two Arm, Open label Phase III study to Assess Efficacy and Safety of Infusion of Amphomul® (Amphotericin B Emulsion) as Compared to Liposomal Amphotericin B in Patients of Visceral Leishmaniasis ...
Antifungal agents may differ in their fungicidal activities against Aspergillus spp. In order to compare the fungicidal activities of voriconazole and amphotericin B against 40 isolates of Aspergillus fumigatus, A. flavus, and A. terreus, we developed a new microbroth colorimetric method for assessing fungicidal activities and determining minimal fungicidal concentrations (MFCs). This methodology follows the antifungal susceptibility testing reference method M-38A for MIC determination. After drug removal and addition of fresh medium, growth of viable conidia adhering to the bottoms of the microtitration wells was assessed by a colorimetric assay of metabolic activity after 24 h of incubation. The new method was faster (six times), reproducible (92 to 97%), and in agreement with culture-based MFCs (91 to 100%). Differential fungicidal activities of voriconazole and amphotericin B were found among the three Aspergillus species, with A. fumigatus and A. flavus having the lowest (1 and 2 mg/liter, ...
Note: This work was presented in part at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 31 January 2000.. Acknowledgments: The authors thank Deanne Fuller, Dr. Tom Davis, and Ann LeMonte for laboratory work; Estella C. Wheatley for preparation of the manuscript; and Cynthia R. Flanigan for help with the management of the data over the course of the clinical trial.. Grant Support: In part by a grant from the National Institute of Allergy and Infectious Diseases to the Mycoses Study Group (contract NO1-A1-15802) and by a grant from the National Center for Research Resources, General Clinical Research Center (contract MO1-RR02558) to participating centers, and by Gilead Sciences, Inc. (formerly NeXstar Pharmaceuticals).. Requests for Single Reprints: Philip C. Johnson, MD, University of Texas-Houston Medical School, Division of General Medicine, 6431 Fannin, MSB 1.122, Houston, TX 77030; e-mail, [email protected] Current Author Addresses: ...
Surgical resection of the "fungus ball" and intravenous amphotericin B is the recommended therapy. If zygomycosis is suspected, prompt amphotericin B therapy should be administered due to the rapid spread and mortality rate of the disease. Amphotericin B (which works by damaging the cell walls of the fungi) is usually administered for a further 4-6 weeks after initial therapy begins to ensure eradication of the infection. Posaconazole has been shown to be effective against zygomycosis, perhaps more so than amphotericin B, but has not yet replaced it as the standard of care. After administration the patient must then be admitted to surgery for removal of the "fungus ball". The disease must be monitored carefully for any signs of reemergence.[5] Surgical therapy can be very drastic, and in some cases of Rhinocerebral disease removal of infected brain tissue may be required. In some cases surgery may be disfiguring because it may involve removal of the palate, nasal cavity, or eye structures.[3] ...
Based on the enhanced fluorescence of amphotericin B in acid solutions, a quantitative assay for this polyene antibiotic has been developed that is sensitive and linear in the range of 0.1 to 10.0 muM. The binding of amphotericin B to Saccharomyces cerevisiae was assayed under various conditions as the amount bound to cells in a dialysis chamber or after centrifugation. Two types of binding were defined: weak, reversible binding occurred at 0 C or higher temperatures and even in the presence of inhibitors of energy metabolism, whereas strong, irreversible binding did not occur at 0 C and was inhibited when energy metabolism was blocked. Only strong binding was correlated with cell killing. Weak binding probably involves the outer layer of the membrane; strong binding probably requires disruption of hydrophobic regions of the cell membrane.
Preface xvi. Abacacavir (Ziagen) 435. Abacavir + Lamivudine + Dolutegravir (Triumeq) 381. Acyclovir (Zovirax) 442. Adefovir (Hepsera) 187. Albendazole (Albenza) 3. Amikacin (Amikin) 9. Amoxicillan 11. Amoxicillin-Clavulanate (Augmentin, Augmentin 600ES, Augmentin XR) 32. Amphotericin B (Fungizone) 169. Amphotericin B Colloidal Dispersion - ABCD (Amphotec) 13. Amphotericin B Lipid Complex (Abelcet) 1. Ampicillin 15. Ampicillin-Sulbactam (Unasyn) 394. Anidulafungin (Eraxis) 149. Artemether/Lumefantrine (Coartem) 92. Artesunate 27. Atazanavir (Reyataz) 317. Atazanavir + Cobicistat (Evotaz) 152. Atovaquone (Mepron) 240. Atovaquone/Proguanil (Malarone) 230. Azithromycin (Zithromax, Zmax) 437. Aztreonam (Azactam) 40. Bedaquiline (Sirturo) 337. Benznidazole 51. Bithionol (Bitin) 57. Capreomycin (Capastat) 62. Caspofungin (Cancidas) 60. Cefaclor 66. Cefadroxil (Duricef) 135. Cefamandole (Mandol) 232. Cefazolin (Ancef) 18. Cefdinir (Omnicef) 270. Cefditoren Pivoxil (Spectracef) 343. Cefepime (Maxipime) ...
Objectives A suspension for oral use which consists of three non-absorbable antibiotics (amphotericin B, colistin and tobramycin) is often used in clinical practice for the selective decontamination of the digestive tract (SDD) of patients in intensive care. Such a therapy is a preventive tool to minimise the risk of pneumonia and bacteraemia in intubated patients. The administration and the treatment results are controversially discussed. One limiting factor for a unique SDD treatment in the hospitals is a lack of adequate data regarding batch formula and stability for such a formulation. Since no detailed procedures, specifications or stability data are available for manufacturing this formulation there may be discrepancies regarding formulation and stability of suspensions prepared in different pharmacies. The aim of this research was to collect the physicochemical and microbiological stability data of a developed, stable standard formulation under defined storage conditions. The ...
A Double-Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients [Bowden R et al. CID 2002;35:359]: The authors report a multicenter randomized, double-blind trial of Amphotec (ABCD) in a dose of 6 mg/kg/day vs. Amphotericin B in a dose of 1.0-1.5 mg/kg/day for treatment of invasive aspergillosis in 174 patients. The diagnosis was considered "proven" if there was a compatible clinical illness and detection of aspergillus by stain or culture from a normally sterile site, or proven with histopathology; it was "probable" if pulmonary with typical clinical and x-ray findings combined with two positive sputum cultures or a positive stain or culture from a BAL. Of the 174 participants, 88 were given ABCD and 86 were given Amphotericin B. Most of the patients had a hematologic malignancy (70%) and/or a bone marrow transplant (42%). Sites of infection included lungs in 66%, sinuses in 15%, and ...
Use Google powered SiteComber to search within various sites for AMPHOTERICIN B. Links to searches for AMPHOTERICIN B can be found here.
SAN FRANCISCO-Amphotericin B lipid complex may be the treatment of choice for patients with hematogenous or invasive candidiasis, Elias J. Anaissie, MD, said at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
NEW ORLEANS-High doses of liposomal amphotericin B are no more effective than low doses in the treatment of invasive aspergillosis in neutropenic patients, European researchers reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1
Amphotericin B modifies the permeability properties of thin lipid membranes formed from solutions containing sheep red cell phospholipids and cholesterol. At 10-6 M amphotericin B, the DC membrane resistance fell from ≈108 to ≈102 ohm-cm2, and the membranes became Cl--, rather than Na+-selective; the permeability coefficients for hydrophilic nonelectrolytes increased in inverse relationship to solute size, and the rate of water flow during osmosis increased 30-fold. These changes may be rationalized by assuming that the interaction of amphotericin B with membrane-bound sterol resulted in the formation of aqueous pores. N-acetylamphotericin B and the methyl ester of N-acetylamphotericin B, but not the smaller ring compounds, filipin, rimocidin, and PA-166, produced comparable permeability changes in identical membranes, and amphotericin B and its derivatives produced similar changes in the properties of membranes formed from phospholipid-free sterol solutions. However, amphotericin B did not ...
In this document, zofran odt price a reference to "intravenous amphotericin B" without a specific dose or other discussion of form should be taken to be a reference to the general use of any of the preparations of amphotericin B, with the understanding that the clinical experience is greatest with amphotericin B deoxycholate for essentially all forms of candidiasis and classes of patien. Qualora avvengano, siosservano sintomi gastrointestinali e alterazioni dell`equilibrio idro-elettrolitico. Herald scotland alcoholics anonymous quiz alcoholics questions alcoholism alcoholism quiz alcoholism research alcoholism treatment alcohol recovery alcohol tax alcohol treatment alcohol use test Alex Balluff Alice in Chains a life gone awry alkies AllyB aloha alternativess to 12-step Alternatives to AA Alternative to Al-Anon Al Unser Jr Alyssa Forcehimes Amanda Leann Kueht amends amends letter Amway amy borieo Amy Lee Coy Amy Winehouse and Richard C. • Flynn TR, Shanti RM, Levi MH, Adamo AK, Kraut RA, ...
Title:Amphotericin B-Loaded Poly(Lactide)-Poly(Ethylene Glycol)-Blend Nanoparticles: Characterization and In Vitro Efficacy and Toxicity. VOLUME: 9 ISSUE: 5. Author(s):Caroline Danziato Rodrigues, Diani Meza Casa, Luciana Facco Dalmolin, Luciana Erzinger Alves de Camargo, Najeh Maissar Khalil and Rubiana Mara Mainardes. Affiliation:Department of Pharmacy, Universidade Estadual do Centro-Oeste/UNICENTRO, Rua Simeão Camargo Varela de Sá 03, 85040-080 Guarapuava, PR - Brazil.. Keywords:Amphotericin B, drug delivery, hemolysis, in vitro antifungal, polymeric nanoparticles.. Abstract:In this study, we developed poly(lactide)-poly(ethylene glycol) (PLA-PEG) blend nanoparticles with variable molecular PEG weights (2, 10, or 20 kDa) to encapsulate antifungal amphotericin B (AmB) and to evaluate its in vitro efficacy in strains of Candida sp. and in vitro cytotoxicity in human erythrocytes. The nanoparticles were prepared using an emulsification/solvent evaporation technique and were characterized with ...
This medicine is for infusion into a vein. It is usually given by a health care professional in a hospital or clinic setting.. If you get this medicine at home, you will be taught how to prepare and give this medicine. Use exactly as directed. Take your medicine at regular intervals. Do not take your medicine more often than directed.. It is important that you put your used needles and syringes in a special sharps container. Do not put them in a trash can. If you do not have a sharps container, call your pharmacist or healthcare provider to get one.. Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.. ...
Amphotericin B, the first commercially significant antifungal drug, has been available for more than 30 years. This polyene macrolide antifungal agent continues to play a major role in the treatment of systemic fungal infections, despite the introduction of newer agents such as the azoles. Given the …
1 Answer - Posted in: fungizone, amphotericin b - Answer: According to manufacturer it should be used in 24 hours of reconstitution
The ability of Candida albicans to form biofilms and adhere to host tissues and biomaterial surfaces is an important factor in its pathogenesis. One of the main characteristics of biofilms is their resistance to broad-spectrum anti-microbial drugs.In the present study the formation of biofilm by C. albicans from different sources was evaluated. In addition, the minimum biofilm inhibitory concentration (MBIC) for two antifungals was evaluated.In total, 120 isolates of C. albicans from different sources (patients with vaginitis, patients with candiduria, bucal cavity and environmental surfaces) were collected. Biofilm formation was determined by the 96-well micro-titeration plate method. MBIC testing was also performed, using the calorimetric indicator resazurin for amphotericin B and fluconazole.The results indicated that 100% of C. albicans isolates from different sources had the ability to form biofilms in vitro. Amongst these isolates, 83.3% of isolates had the maximum potential (4+) to form biofilms,
Deep seated candidoses are the most common invasive fungal infections occurring in various categories of patients including those with cancer, burns as well as patients with AIDS or undergoing organ transplantation. Various clinical entities have to be distinguished with implications for diagnostic procedures as well as for adequate therapy. During the last decade, tremendous progress has been achieved leading to a major reduction of mortality attributable for candidaemia from 80 % (in the seventies) to 40 % in the nineties, mainly due to early empiric antifungal and better prophylaxis treatment. Other antifungal strategies than conventional amphotericin B are now available and have been shown effective, in particular, new modalities to administer amphotericin B including various lipid formulations, but also new azoles and mainly the triazoles such as fluconazole and itraconazole. Fluconazole has been shown effective as prophylaxis of candidosis including in patients undergoing bone marrow ...
There are very few drug delivery systems that target key organs via the oral route, as oral delivery advances normally address gastrointestinal drug dissolution, permeation, and stability. Here we introduce a nanomedicine in which nanoparticles, while also protecting the drug from gastric degradation, are taken up by the gastrointestinal epithelia and transported to the lung, liver, and spleen, thus selectively enhancing drug bioavailability in these target organs and diminishing kidney exposure (relevant to nephrotoxic drugs). Our work demonstrates, for the first time, that oral particle uptake and translocation to specific organs may be used to achieve a beneficial therapeutic response. We have illustrated this using amphotericin B, a nephrotoxic drug encapsulated within N-palmitoyl-N-methyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycol chitosan (GCPQ) nanoparticles, and have evidenced our approach in three separate disease states (visceral leishmaniasis, candidiasis, and aspergillosis) using ...
One randomized, open-label, active-controlled study was conducted to evaluate the efficacy of IMPAVIDO in the treatment of visceral leishmaniasis in Bihar, India, an area where L. donovani is known epidemiologically to be the prevalent infecting species. Patients ≥ 12 years of age with clinical signs and symptoms compatible with visceral leishmaniasis (fever, splenomegaly, and cytopenia) confirmed by the presence of Leishmania amastigotes in aspirates of spleen or bone marrow were randomized to receive oral IMPAVIDO or intravenous amphotericin B deoxycholate in a 3:1 ratio. Patients weighing ≥ 25 kg received an IMPAVIDO 50 mg capsule with meals twice a day. Patients weighing , 25 kg received an IMPAVIDO 50 mg capsule with meals once a day in the morning. Weight ranged between 15 and 67 kg (mean weight 38.6 kg) and BMI ranged between 8.2 and 24 (mean 16.1). No patient weighed more than 70kg. Amphotericin B was administered intravenously over 6 continuous hours at 1 mg/kg every other day for ...
193 medications are known to interact with amphotericin b liposomal. Includes Aranesp (darbepoetin alfa), Bumex (bumetanide), CellCept (mycophenolate mofetil).
[Ion channels, induced by amphotericin B introduced unilaterally into lipid bilayers].: Single ionic channels of approximately 10 pS in magnitude and approximat
Sigma-Aldrich offers Sigma-A2411, Amphotericin B from Streptomyces sp. for your research needs. Find product specific information including CAS, MSDS, protocols and references.
Gentaur molecular products has all kinds of products like :search , PhytoTechnology Laboratories \ AMPHOTERICIN B \ A119-5G for more molecular products just contact us
Nachricht: iCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program (5962087) - 28.11.16 - News
Gentaur molecular products has all kinds of products like :search , Biosera \ Amphotericin B _ 10g \ PM-A4121/10 for more molecular products just contact us
The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format. By default, clicking on the export buttons will result in a download of the allowed maximum amount of items. To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export. After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format. ...
In this randomized, double-blind, dose-ranging, multicenter trial, 84 patients with visceral leishmaniasis refractory to antimony therapy were administered liposomal amphotericin B (AmBisome) at cumulative doses of 3.75, 7.5, and 15.0 mg/kg for 5 consecutive days. Posttreatment apparent cure and definite cure were assessed at 2 weeks and 6 months after the end of therapy, respectively. Mild to moderate infusion-related fever and rigors were seen in 29 and 44% of patients, respectively. One patient each in the 3.75- and 7.5-mg groups had detectable parasites on splenic smear at posttreatment evaluation. At 6 months' follow-up, however, 2, 1, and 1 patients relapsed in the 3.75-, 7.5-, and 15.0-mg groups, resulting in definite cure rates of 89, 93, and 97%, respectively. There was no significant difference in the cure rates of the 3 groups. Low-dose liposomal amphotericin B given for 5 days can cure most patients with Indian kala-azar.
The in vitro and in vivo toxicities and activities of MS-8209, a new hydrosoluble amphotericin B (deoxycholate-amphotericin B [D-AmB]; Fungizone) derivative, were studied. In vitro, MS-8209 was less toxic than AmB against renal tubular cells in primary culture and less active against Candida albicans and Cryptococcus neoformans. However, at 10-fold the AmB concentration, MS-8209 in vitro antifungal activity paralleled that of AmB. Fifty-percent lethal doses of MS-8209 and D-AmB in OF1 noninfected mice were 26 and 2.3 mg/kg, respectively. Therapeutic efficacy of MS-8209 was assessed in murine candidiasis, cryptococcosis, and aspergillosis. In each model of infection, we determined the maximum tolerated dosages of MS-8209 and D-AmB, i.e., the dosage inducing less than 15% mortality due to toxicity; the efficacies of MS-8209 and D-AmB at their respective maximum tolerated dosages were compared. In candidiasis, MS-8209 (15 mg/kg) significantly increased the survival time compared with D-AmB (0.5 ...
A 32-week neonate weighing 2,300 g at birth with fungemia due to Candida albicanssubsequently developed multifocal osteoarthritis of the lower extremities due to the same organism during therapy...
However, because of the high cost of the lipid preparations, their use at many centers is reserved for patients who fail to respond to standard amphotericin B. Since the side effects of the formulations differ, unnecessary switching from one to another is not recommended. Although fluconazole is efficacious in the treatment of infections due to many Candida spp., its use against serious fungal infections in immunocompromised patients is limited by its narrow spectrum: it has no activity against Aspergillus or against several non-albicans Candida spp.The release of newer broad-spectrum azoles (such as voriconazole and posaconazole) has provided another option for the treatment of Aspergillus infection (including CNS infection, in which amphotericin B has usually failed). In fact, experience indicates that these drugs may well supplant amphotericin B as the mainstay of treatment because of their lesser toxicity and better penetration into cerebrospinal fluid and other sites. Clinicians should be ...
Acute renal failure occurred in a quarter of the patients. Correlates of ARF at the beginning and during the course of amphotericin therapy were identified and then combined to allow stratification according to ARF risk. These data also provide evidence for guidelines for the selection of patients f …
Sixty-nine patients between the ages of 18 and 80 with invasive aspergillosis were enrolled in an open-label, noncomparative study to evaluate the safety, tolerability, and efficacy of caspofungin. Enrolled patients had previously been refractory to or intolerant of other antifungal therapy (ies). Refractory patients were classified as those who had disease progression or failed to improve despite therapy for at least 7 days with amphotericin B, lipid formulations of amphotericin B, itraconazole, or an investigational azole with reported activity against Aspergillus. Intolerance to previous therapy was defined as a doubling of creatinine (or creatinine ≥2.5 mg/dL while on therapy), other acute reactions, or infusion-related toxicity. To be included in the study, patients with pulmonary disease must have had definite (positive tissue histopathology or positive culture from tissue obtained by an invasive procedure) or probable (positive radiographic or computed tomography evidence with ...
Studies have found evidence that amphotericin opens up ion channels in membranes, perhaps making them leakier to charged atoms that could disrupt a cell. Most scientists assumed that this was the drugs main mode of action. But the evidence also suggested that amphotericin interacted with sterols, such as cholesterol in animal cells and ergosterol in yeast. Rienstra and Burke focused on amphotericins influence on sterols, hypothesizing that this might be a key to its toxicity ...
Amphotericin[edit]. Amphotericin B, introduced in 1957, remains the treatment of choice for severe infections. It is usually ... In a case report of a 23-year-old Black male with HIV and coccidioidal meningitis, combination therapy of amphotericin B and ... In very severe cases, combination therapy with amphotericin B and an azole have been postulated, although no trials have been ... It can be administered either in the classic amphotericin B deoxycholate formulation or as a lipid formulation. No studies have ...
Amphotericin B. This antifungal medication is delivered intravenously. Many patients, however, cannot tolerate Amphotericin B ... Lipid formulations of amphotericin B are usually recommended instead of amphotericin B deoxycholate because of a better adverse ... Amphotericin B can be used for severe infection during pregnancy. For children with disseminated or severe disease, ... In case of sporotrichosis meningitis, the patient may be given a combination of Amphotericin B and 5-fluorocytosine/Flucytosine ...
Such drugs include other aminoglycosides; the antiviral acyclovir; the antifungal amphotericin B; the antibiotics bacitracin, ...
Systemic: amphotericin B#, hamycin‡. Squalene monooxygenase. inhibitors. Allylamines. *Topical: naftifine. *terbinafine. ...
Amphotericin B is nephrotoxic when given intravenously. As a polyene's hydrophobic chain is shortened, its sterol binding ... Baginski M, Czub J (June 2009). "Amphotericin B and its new derivatives - mode of action". Current Drug Metabolism. 10 (5): 459 ... However, at therapeutic doses, some amphotericin B may bind to animal membrane cholesterol, increasing the risk of human ...
Systemic: amphotericin B#, hamycin‡. Squalene monooxygenase. inhibitors. Allylamines. *Topical: naftifine. *terbinafine. ...
Amphotericin B is another option. Among individuals being treated in intensive care units, the mortality rate is about 30-50% ... A number of weeks of intravenous amphotericin B may be used as an alternative. In certain groups at very high risk, antifungal ... By mouth or intravenous fluconazole, itraconazole, or amphotericin B may be used if these do not work. A number of topical ... treatment with amphotericin B may be necessary. Vaginal yeast infections are typically treated with topical antifungal agents. ...
Amphotericin B has been replaced by safer agents in most circumstances, but is still used, despite its side effects, for life- ... Amphotericin B, an antifungal drug, targets ergosterol. It binds physically to ergosterol within the membrane, thus creating a ... Ellis D (February 2002). "Amphotericin B: spectrum and resistance". J. Antimicrob. Chemother. 49 Suppl 1: 7-10. doi:10.1093/jac ...
Polyene antibiotic amphotericin B. L. infantum[23] *Amphotericin B. *Meglumine antimoniate. *Pentavalent antimonials ...
Another antimicrobial drug amphotericin B is also commonly used. Liposomal amphotericin B (L-AmB) has been a drug of choice in ... Further, amphotericin B has severe adverse effects. Its acute effects includes nausea, vomiting, rigors, fever, hypertension or ... Laniado-Laborín, Rafael; Cabrales-Vargas, Maria Noemí (2009). "Amphotericin B: side effects and toxicity". Revista ...
Amphotericin B has also been used. The prognosis for chromoblastomycosis is very good for small lesions. Severe cases are ... treatment with a combination of amphotericin B and 5-flucytosine". Br. J. Dermatol. 152 (3): 560-4. doi:10.1111/j.1365- ... "Extensive chromoblastomycosis caused by Fonsecaea pedrosoi successfully treated with a combination of amphotericin B and ...
"Amphotec (amphotericin b) injection, lipid complex". U.S. National Library of Medicine. Department of Health & Human Services ... amphotericin b), an injectable anti-fungal drug Topotecan Hydrochloride for Injection, approved for certain indications of ...
Amphotericin B is nephrotoxic when given intravenously. As a polyene's hydrophobic chain is shortened, its sterol binding ... Amphotericin B Candicidin Filipin - 35 carbons, binds to cholesterol (toxic) Hamycin Natamycin - 33 carbons, binds well to ... However, at therapeutic doses, some amphotericin B may bind to animal membrane cholesterol, increasing the risk of human ... Antimicrobial Fungicide Baginski M, Czub B (Jun 2009). "Amphotericin B and its new derivatives". Current Drug Metabolism. 10 (5 ...
Treatment with amphotericin B has been reported. Prototheca has been thought to be a mutant of Chlorella, a type of single- ...
Amphotericin B, nystatin, and natamycin are examples of polyene antimycotics. They are a subgroup of macrolides. Their chemical ... "A labile point in mutant amphotericin polyketide synthases". Biotechnol Lett. 33 (6): 1121-6. doi:10.1007/s10529-011-0538-3. ...
Wilson, Rickey (1 July 1979). "Toxicity of Amphotericin B in Children With Cancer". Archives of Pediatrics & Adolescent ...
Mishra proposed the use of Amphotericin B (Fungizone) to combat the disease through an article he published in Lancet in 1991. ... India portal Leishmaniasis Amphotericin B "India Medical Times". India Medical Times. 2014. Retrieved November 5, 2014. "News ... and its treatment using Amphotericin B, regarded by many as a pioneering attempt. The Government of India honoured him, in 2014 ...
... is susceptible to amphotericin B and Flucytosine. Rhodotorula can also cause infections in animals. There have been ...
Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific. European ... Richie DL, Ghannoum MA, Isham N, Thompson KV, Ryder NS (2012). "Nonspecific effect of Mycograb on amphotericin B MIC". ... intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice ...
Amphotericin B deoxycholate is the most common treatment antifungal agent used to treat Candida infections. Topical antifungal ... Micafungin, compared to amphotericin B, it is more efficient. Anidulafungin results are similar to Caspofungin and Micafungin. ... For invasive disease, treatments include amphotericin B, echinocandins, or extended-spectrum triazole antifungals. In the ...
McCurdy DK, Frederic M, Elkinton JR (1968). "Renal tubular acidosis due to amphotericin B". N. Engl. J. Med. 278 (3): 124-30. ... Toxins, including ifosfamide (more commonly causing pRTA than dRTA), toluene, lithium carbonate and amphotericin B. Chronic ...
Chunn CJ, Starr PR, Gilbert DN (August 1977). "Neutrophil toxicity of amphotericin B". Antimicrobial Agents and Chemotherapy. ...
Amphotericin B. *Evt. ekstra Fluconazol mod Candida. *Interferon gamma 3x ugtl.: Nedsætter hyppigheden af infektioner med 70 % ...
"Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis". The New England Journal of Medicine. 347 (6 ...
Amphotericin B may also be used to reduce fungal load. In the mouse study, both drugs decreased the amount of hyphae in ... Amphotericin B is the most potent antifungal drug available to treat mucormycosis. When given intravenously in the deoxycholate ... For this reason, it is often replaced with liposomal amphotericin B, a lipid-based formulation with fewer adverse side effects ... and anti-fungal therapy with drugs such as posaconazole and amphotericin B. Members of the order Mucorales generally infect ...
Therapy with amphotericin B, itraconazole, or the investigationaI triazole SCH 56592 was conducted for 10 days. Half the mice ... Therapy with amphotericin B, itraconazole, or the investigationaI triazole SCH 56592 was conducted for 10 days. Half the mice ... Therapy with amphotericin B, itraconazole, or the investigationaI triazole SCH 56592 was conducted for 10 days. Half the mice ... Therapy with amphotericin B, itraconazole, or the investigationaI triazole SCH 56592 was conducted for 10 days. Half the mice ...
The patient was treated with amphotericin B and itraconazole with a good clinical response (Rev Méd Chile 2003; 131: 77-80). ...
The patient was given 430 mg of amphotericin B lipid complex every 24 hours. As a result of the patients worsening condition, ... Until the advent of amphotericin B in the 1950s, mucormycosis was a universally fatal fungal infection. One case series by ... Early diagnosis and intervention with amphotericin B lipid complex and surgery directly correlated with patient survival.8 ... Therapy with amphotericin B lipid complex. Arch Intern Med. 1996;156:337-340. ...
22. Carter R. Sensitivity to amphotericin B of a Naegleria sp. isolated from a case of primary amoebic meningoencephalitis. J ... In 1969, Carter was able to demonstrate the sensitivity of the organism to amphotericin B (AMB) and it has remained the ... The patient was commenced on intrathecal amphotericin, with no improvement in his clinical state. The organism seen in the CSF ... Some survivors have been reported; these patients received early treatment with amphotericin B in combination with a variety of ...
He was treated with amphotericin B and rifampin, but postmortem examination showed persistent, disseminated infection. ... He was treated with amphotericin B and rifampin, but postmortem examination showed persistent, disseminated infection.", ... He was treated with amphotericin B and rifampin, but postmortem examination showed persistent, disseminated infection. ... He was treated with amphotericin B and rifampin, but postmortem examination showed persistent, disseminated infection. ...
The patient clinically improved following intravenous meropenem, vancomisin, amphotericin B and caspofungin empirically for one ...
A separate antifungal compound, amphotericin B, has been employed in aerosolised form to treat invasive infection with ...
... is a macrolide antibiotic (CHEBI:25105) amphotericin B (CHEBI:2682) is a polyene antibiotic (CHEBI: ... amphotericin B (CHEBI:2682) has role bacterial metabolite (CHEBI:76969) amphotericin B (CHEBI:2682) is a antibiotic antifungal ... amphotericin B methyl ester (CHEBI:277842) has functional parent amphotericin B (CHEBI:2682). ... CHEBI:2682 - amphotericin B. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. ...
Five cases are described in which fear of the possibly hazardous effects of giving amphotericin to patients with kidney disease ... Amphotericin Pharmacophobia. Br Med J 1973; 4 doi: https://doi.org/10.1136/bmj.4.5890.460 (Published 24 November 1973) Cite ... resulted in death from progressive infection by an amphotericin-sensitive fungus (Cryptococcus neoformans in three cases, ...
AmBisome infusion contains the active ingredient amphotericin, which is a type of medicine called an antifungal. It is used to ... AmBisome (amphotericin). AmBisome infusion contains the active ingredient amphotericin, which is a type of medicine called an ... amphotericin must be given by a drip into a vein (intravenous infusion). Unfortunately amphotericin given in this way commonly ... Amphotericin may be less effective at treating infection if it is used in combination with azole-type antifungals such as ...
Fungizone infusion contains the active ingredient amphotericin, which is a type of medicine called an antifungal. It is used to ... Fungizone (amphotericin). Fungizone infusion contains the active ingredient amphotericin, which is a type of medicine called an ... Fungizone infusion is a conventional water-based form of amphotericin. Unfortunately, this form of amphotericin commonly causes ... Amphotericin may be less effective at treating infection if it is used in combination with azole-type antifungals such as ...
... type is the antifungal agent amphotericin B, which binds to a specific molecule (ergosterol) found in fungal cells. This ... Other articles where Amphotericin B is discussed: drug: Membrane lipids: … ... Polyenes, such as amphotericin B and nystatin, are macrolide antibiotics made up of alternating conjugated double bonds. The ... type is the antifungal agent amphotericin B, which binds to a specific molecule (ergosterol) found in fungal cells. This ...
Two amphotericins, amphotericin A and amphotericin B, are known, but only B is used clinically, because it is significantly ... Amphotericin A is almost identical to amphotericin B (having a C=C double bond between the 27th and 28th carbons), but has ... This is amphotericin Bs primary effect as an antifungal agent. It has been found that the amphotericin B/ergosterol ... As the original formulation of amphotericin, it is often referred to as "conventional" amphotericin. In order to improve the ...
Effects of Fluid and Electrolyte Management on Amphotericin B-Induced Nephrotoxicity Among Extremely Low Birth Weight Infants ...
Amphotericin B Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... You may receive amphotericin B injection in a hospital or you may use the medication at home. If you will be using amphotericin ... Before receiving amphotericin B injection,. *tell your doctor and pharmacist if you are allergic to amphotericin B, any other ... Amphotericin B injection is used to treat serious and potentially life-threatening fungal infections. Amphotericin B injection ...
I work peds onc and we use a lot of amphotericin B and liposomal ampho if the kids cant handle the regular. We treat regular ... I work peds onc and we use a lot of amphotericin B and liposomal ampho if the kids cant handle the regular. We treat regular ... I have had children develop seizures from amphotericin. Some of the other drugs you listed also change the seizure threshold. ...
Amphotericin B Liposomal Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving amphotericin B liposomal injection,. *tell your doctor and pharmacist if you are allergic to amphotericin B, ... You may receive amphotericin B liposomal injection in a hospital or you may use the medication at home. If you will be using ... Amphotericin B liposomal injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go ...
Many of the important biologic properties of amphotericin B may be ascribed to binding by certain sterols in fungal and ... Many of the important biologic properties of amphotericin B may be ascribed to binding by certain sterols in fungal and ... Bennett J.E. (1976) Review of Amphotericin B. In: Williams J.D., Geddes A.M. (eds) Parasites, Fungi, and Viruses. Chemotherapy ... Avid binding to serum proteins, probably coupled at least in part by cholesterol, makes amphotericin B equilibrate slowly with ...
A list of US medications equivalent to Ambisome Liposomal Amphotericin B is available on the Drugs.com website. ... Ambisome Liposomal Amphotericin B is a medicine available in a number of countries worldwide. ... Amphotericin B. Amphotericin B liposomal (a derivative of Amphotericin B) is reported as an ingredient of Ambisome Liposomal ... Ambisome Liposomal Amphotericin B. Ambisome Liposomal Amphotericin B may be available in the countries listed below. ...
Red man syndrome associated with amphotericin B.. BMJ 1990; 300 doi: https://doi.org/10.1136/bmj.300.6737.1468 (Published 02 ...
Easy-to-read patient leaflet for Amphotericin B (Lipid Complex). Includes indications, proper use, special instructions, ... Amphotericin B (Lipid Complex). Generic Name: Amphotericin B (Lipid Complex) (am foe TER i sin bee LIP id KOM pleks). Brand ... What do I need to tell my doctor BEFORE I take Amphotericin B?. *If you have an allergy to amphotericin or any other part of ... How do I store and/or throw out Amphotericin B?. *If you need to store amphotericin B (lipid complex) at home, talk with your ...
... is used to treat serious, life-threatening fungal infections including leishmaniasis, and a certain ... Amphotericin B liposomal is an antifungal medication that fights infections caused by fungus. ... form of meningitis in people infected with HIV (human immunodeficiency virus). Amphotericin B... ... How is amphotericin B liposomal given?. Amphotericin B liposomal is injected into a vein through an IV. You will receive this ...
Read more about the prescription drug AMPHOTERICIN - INJECTION. ... GENERIC NAME: AMPHOTERICIN - INJECTION (AM-foe-TER-i-sin). ... Consumer information about the medication AMPHOTERICIN - INJECTION (Fungizone), includes side effects, drug interactions, ... WARNING: Amphotericin should be used only to treat serious, possibly fatal fungal infections. This medication should not be ... PRECAUTIONS: Before using amphotericin, tell your doctor or pharmacist if you are allergic to it; or if you have any other ...
Amphotericin B is an antifungal agent that is used both topically and systemically for various fungal infections, especially ... Amphotericin B (Fungizone). Amphotericin B is an antifungal agent that is used both topically and systemically for various ...
AMBISOME (amphotericin b) injection, powder, lyophilized, for solution NDC Code(s): 0469-3051-30 ... amphotec (Amphotericin B) injection, lipid complex NDC Code(s): 64116-021-01, 64116-025-01 ... AMPHOTERICIN B injection, powder, lyophilized, for solution NDC Code(s): 39822-1055-5 ... ABELCET (amphotericin b, dimyristoylphosphatidylcholine, dl- and dimyristoylphosphatidylglycerol, dl-) injection NDC Code(s): ...
  • DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program 28.11.2016 / 14:00 The issuer is solely responsible for the content of this announcement. (ariva.de)
  • The distribution of amphotericin B MICs by Etest with RPMI ranged from 0.032 to 16 μg/ml and was bimodal. (asm.org)
  • They created a derivative that could bind ergosterol but could not form ion channels , and tested it against the original amphotericin. (phys.org)
  • But the ergosterol-binding, non-channel-forming derivative was almost equally potent to natural amphotericin against both of the yeast cell lines the researchers tested, once of which is highly pathogenic in humans. (phys.org)
  • The results are all consistent with the same conclusion: In contrast to half a century of prior study and the textbook-classic model, amphotericin kills yeast by simply binding ergosterol," Burke said. (phys.org)
  • Amphotericin B increases fungal membrane permeability and cell death by binding ergosterol. (arvojournals.org)
  • Doctors and researchers do know that amphotericin creates ion channels that permeate the cell membrane. (phys.org)
  • The membrane-active antibiotics amphotericin B and polymyxin B enhanced the action of rifampicin, rifampicin analogs, and tetracycline against macromolecular synthesis and growth of mouse L-cells, human HeLa cells, and KB cells in tissue culture. (aacrjournals.org)
  • In the subsample (N = 231), independent correlates of ARF were maximum daily amphotericin dosage, location at the time of initiation of amphotericin therapy, and concomitant use of cyclosporine. (nih.gov)